UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Bralten J
(2021)
Genetic underpinnings of sociability in the general population
in Neuropsychopharmacology
Brandes N
(2021)
Genetic association studies of alterations in protein function expose recessive effects on cancer predisposition
in Scientific Reports
Brandes N
(2020)
PWAS: proteome-wide association study-linking genes and phenotypes by functional variation in proteins.
in Genome biology
Brassard D
(2022)
Greater adherence to the 2019 Canada's Food Guide recommendations on healthy food choices reduces the risk of cardiovascular disease in adults: a prospective analysis of UK Biobank data.
in The American journal of clinical nutrition
Brayner B
(2022)
Longitudinal Associations Between Fat-Derived Dietary Patterns and Early Markers of Cardiovascular Disease Risk in the UK Biobank Study.
in Journal of the American Heart Association
Brayner B
(2021)
Dietary Patterns Characterized by Fat Type in Association with Obesity and Type 2 Diabetes: A Longitudinal Study of UK Biobank Participants.
in The Journal of nutrition
Brazel DM
(2019)
Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use.
in Biological psychiatry
Brcic L
(2020)
Medical and neurobehavioural phenotypes in carriers of X-linked ichthyosis-associated genetic deletions in the UK Biobank.
in Journal of medical genetics
Briggs SEW
(2022)
Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study.
in BMJ (Clinical research ed.)
Brito Nunes C
(2023)
Mendelian randomization study of maternal coffee consumption and its influence on birthweight, stillbirth, miscarriage, gestational age and pre-term birth.
in International journal of epidemiology
Broce IJ
(2019)
Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease.
in Acta neuropathologica
Brouwer RM
(2022)
Genetic variants associated with longitudinal changes in brain structure across the lifespan.
in Nature neuroscience
Brown DW
(2022)
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis.
in Nature communications
Browning B
(2022)
Genotype error biases trio-based estimates of haplotype phase accuracy
Browning B
(2022)
Statistical phasing of 150,119 sequenced genomes in the UK Biobank
Browning BL
(2021)
Fast two-stage phasing of large-scale sequence data.
in American journal of human genetics
Browning BL
(2023)
Statistical phasing of 150,119 sequenced genomes in the UK Biobank.
in American journal of human genetics
Brumpton B
(2020)
Avoiding dynastic, assortative mating, and population stratification biases in Mendelian randomization through within-family analyses.
in Nature communications
Buchanan CR
(2020)
The effect of network thresholding and weighting on structural brain networks in the UK Biobank.
in NeuroImage
Budu-Aggrey A
(2019)
Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study.
in PLoS medicine
Budu-Aggrey A
(2021)
Investigating the causal relationship between allergic disease and mental health.
in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Buergel T
(2022)
Metabolomic profiles predict individual multidisease outcomes.
in Nature medicine
Burch KS
(2022)
Partitioning gene-level contributions to complex-trait heritability by allele frequency identifies disease-relevant genes.
in American journal of human genetics
Burgoine T
(2018)
Examining the interaction of fast-food outlet exposure and income on diet and obesity: evidence from 51,361 UK Biobank participants.
in The international journal of behavioral nutrition and physical activity
Burns AC
(2021)
Time spent in outdoor light is associated with mood, sleep, and circadian rhythm-related outcomes: A cross-sectional and longitudinal study in over 400,000 UK Biobank participants.
in Journal of affective disorders
Bushnell CD
(2023)
Stroke in Women and Unique Risk Factors.
in Stroke
Butler-Laporte G
(2020)
Genetic Determinants of Antibody-Mediated Immune Responses to Infectious Diseases Agents: A Genome-Wide and HLA Association Study.
in Open forum infectious diseases
Butler-Laporte G
(2021)
Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study.
in PLoS medicine
Butler-Laporte G
(2020)
Elevated body mass index is associated with an increased risk of infectious disease admissions and mortality: a mendelian randomization study.
in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Buto P
(2022)
Genetic Risk Score for Alzheimer's Disease Predicts Brain Volume Differences in Mid- and Late-life in UK Biobank Participants
in Alzheimer's & Dementia
Byg LM
(2023)
Genetic liability to bipolar disorder and body mass index: A bidirectional two-sample Mendelian randomization study.
in Bipolar disorders
Byrne DJF
(2022)
Significantly increased risk of chronic obstructive pulmonary disease amongst adults with predominantly mild congenital heart disease.
in Scientific reports
Byrne S
(2023)
Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types.
in International journal of epidemiology
Bédard S
(2022)
Automatic measure and normalization of spinal cord cross-sectional area using the pontomedullary junction.
in Frontiers in neuroimaging
Bøstrand SMK
(2022)
Associations between alcohol use and accelerated biological ageing.
in Addiction biology
Cabanas-Sánchez V
(2022)
Muscle strength and incidence of depression and anxiety: findings from the UK Biobank prospective cohort study.
in Journal of cachexia, sarcopenia and muscle
Cabrera-Mendoza B
(2022)
The association of obesity-related traits on COVID-19 severity and hospitalization is affected by socio-economic status: a multivariable Mendelian randomization study.
in International journal of epidemiology
Cadby G
(2022)
Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease.
in Nature communications
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |